Clinical Trials Browser

Phase 1/2 × Uveal Melanoma × RNA, Messenger × Clear all

NCT00929019 2018-12-07

Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients

Phase 1/2 Terminated

Uveal Melanoma